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« La filosofia è scritta in questo grandissimo libro che continuamente ci sta aperto 28 
innanzi a gli occhi (io dico l'universo), ma non si può intendere se prima non s'impara 29 
a intender la lingua, e conoscer i caratteri, ne' quali è scritto. Egli è scritto in lingua 30 
matematica, e i caratteri son triangoli, cerchi, ed altre figure geometriche, senza i 31 
quali mezzi è impossibile a intenderne umanamente parola; senza questi è un aggirarsi 32 
vanamente per un oscuro laberinto.»  (Galileo Galilei, Il Saggiatore, Cap. VI) 33 
 34 
Abstract 35 
In this perspective article we discuss the role of contemporary biomechanics in the light of recent applications 36 
such as the development of the so-called Virtual Physiological Human technologies for physiology-based in 37 
silico medicine. In order to build Virtual Physiological Human (VPH) models, computer models that capture and 38 
integrate the complex systemic dynamics of living organisms across radically different space-time scales, we 39 
need to re-formulate a vast body of existing biology and physiology knowledge so that it is formulated as a 40 
quantitative hypothesis, which can be expressed in mathematical terms. Once the predictive accuracy of these 41 
models is confirmed against controlled experiments and against clinical observations, we will have VPH model 42 
that can reliably predict certain quantitative changes in health status of a given patient, but also, more important, 43 
we will have a theory, in the true meaning this word has in the scientific method. In this scenario, biomechanics 44 
plays a very important role: biomechanics is one of the few areas of life sciences where we attempt to build full 45 
                                                
1
 Some of the concepts exposed here were first presented at the 7th World Congress of Biomechanics, 
held in Boston (USA) in July 2014, in the plenary lecture entitled:” To Infinity and Beyond 
Musculoskeletal Biomechanics in the Age of the Virtual Physiological Human”. 
 
mechanistic explanations based on quantitative observations; in other words, we investigate living organisms 46 
like physical systems. This is in our opinion a Copernican revolution, around which the scope of biomechanics 47 
should be re-defined.  Thus, we propose a new definition for our research domain: “Biomechanics is the study of 48 
living organisms as mechanistic systems”.   49 
 50 
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 53 
In silico medicine (ISM) is usually defined as the use of computer simulation in the provision 54 
of healthcare (Wikipedia contributors, 2014). In this sense, ISM appears primarily an 55 
engineering challenge, where existing knowledge about the physiology and the pathology of 56 
the human body is captured in computer models, combined with specific quantitative data 57 
about the anatomy, physiology, pathology, and biology of the patient, and used to make 58 
predictions useful in prevention, diagnosis, prognosis, treatment planning, rehabilitation 59 
planning, and monitoring (Bassingthwaighte, 1997; Popel et al., 1998; Hunter et al., 2002; 60 
STEP Consortium, 2007).   61 
While this perspective is essential, and it defines the path to translate this research into true 62 
socioeconomic impact (Thiel et al., 2009; Viceconti, M., and McCulloch, 2011; Thiel et al., 63 
2013), it tends to hide a much more fundamental perspective: that in silico medicine is a new 64 
science. 65 
Admittedly, this status emerges somehow from necessity. In order to build Virtual 66 
Physiological Human (VPH) models, computer models that capture and integrate the complex 67 
systemic dynamics of living organisms across radically different space-time scales, we need 68 
to re-formulate a vast body of existing biology and physiology knowledge so that it is 69 
formulated as a quantitative hypothesis, which can be expressed in mathematical terms. Some 70 
physiologists pioneered this approach: for example Noble’s seminal work in cardiac 71 
electrophysiology (Noble, 1960), or Guyton’ model for circulatory control (Guyton et al., 72 
1972). 73 
We then need to attempt the falsification of these quantitative hypotheses by means of 74 
quantitative experiments. However, due to the complexity of living organisms, each 75 
experiment must trade complexity (some authors refer to this as realism) with controllability. 76 
If we experiment with an intervention on a patient or a volunteer, there are limited 77 
possibilities to control a number of co-factors that can influence the outcome; in other words 78 
our ability to control the experiment is somehow limited. So we resort to experimental 79 
models: the simpler is the model, the higher is the level of control we can have on it.  So an 80 
animal model is much more complex (and difficult to control) than a ex vivo tissue culture 81 
model, which in turn is much more complex and much less controllable than an in vitro 82 
experiment.   This is why in the most advanced VPH models we falsify our hypotheses by 83 
using progressively more complex experimental models (or progressively reduced 84 
controllability), typically starting in vitro, then move to animal models, and then last to 85 
human experimentation. In this process our understanding of the limitations of the theory at 86 
hand increases, we unravel the co-factors that interfere with the observations, and we are thus 87 
in a much stronger position to interpret the outcomes of clinical experimentation. 88 
But at the end of this tortuous and incredibly challenging process not only we will have a 89 
VPH model that can reliably predict certain quantitative changes in health status of a given 90 
patient, but also, more important, we will have a theory, in the true meaning this word has in 91 
the scientific method. This is a new science where researchers trained in biology, physiology, 92 
chemistry, mathematics, physics, engineering, and medicine work together sharing this 93 
epistemology.  94 
It is a new science where the methods of synthetic biology, cellular biology, tissue 95 
engineering, animal experimentation, or experimental biophysics (biomechanics, 96 
bioelectricity, biochemistry, etc.) are used not as an end but as a mean to inform and validate 97 
new quantitative hypotheses, and the computer models that embody them. In this sense ISM 98 
is not a computational science, nor an experimental science; it is in the continuous exchange 99 
between models and experiments that this new science manifest itself. 100 
In this scenario, biomechanics plays a very important role, much more important than it was 101 
recognised so far.  First, biology has historically privileged the chemical side of all processes, 102 
neglecting the role that mechanical factors play in most physiological and pathological 103 
processes; we need a lot more of biomechanical knowledge at all space-time scales, from the 104 
whole body neuromuscular coordination to the effect of nucleus deformation on the synthesis 105 
of proteins within a single cell. 106 
But the potential role that biomechanics can play in this context is much broader. 107 
Traditionally biomechanics is defined as “ […] the study of the structure and function of 108 
biological systems by means of the methods of mechanics” [Hatze, 1974].  This reflects an 109 
old academic subdivision of physical sciences around the fundamental types of energy 110 
(mechanical, chemical, electromagnetic); but as biomechanics develop its research agenda 111 
also at organ, tissue, and cell scales, the separation of mechanical factors from the chemical or 112 
electrical ones becomes arbitrary, to say the least.   113 
So what is the role of biomechanics in the 21
st
 century?  It is interesting to notice that many 114 
VPH specialists emerged from biomechanics, and that the musculoskeletal and cardiovascular 115 
systems (historically the most biomechanics-intensive) are the two organ systems where the 116 
use of VPH approaches has yield the best results so far.  The reason is simple: biomechanics 117 
is one of the few areas of life sciences where we attempt to build full mechanistic 118 
explanations based on quantitative observations; in other words, we investigate living 119 
organisms like physical systems.  120 
In the past the idea that living organisms could be reduced to physical systems has been 121 
debated, for example by Ernst Mayr (Mayr, 2004), claiming that biology could not be reduced 122 
to physics and chemistry, and had its own unique epistemological space.  Most of the 123 
arguments of this thesis are based on limitations, in the sense that they suggest that the 124 
complexity of living organisms prevents to investigate them as physical systems, and thus a 125 
new epistemology must be used, that of biology. It is unquestionable that there are broad 126 
areas such as evolution (Mayr himself was an evolutionary biologist) where this is true; but 127 
the constant improvement of experimental and computational technologies is expanding the 128 
territory of biological problems were a full mechanistic approach is viable. An evidence of 129 
this is the appearance of Systems Biology, where a bottom-up mechanistic approach is 130 
advocated.  131 
And here is, in our opinion, the unique space for biomechanics research: where a mechanistic 132 
approach is possible, who better than a biomechanician can pick up this challenge?  This is in 133 
our opinion a Copernican revolution, around which the scope of biomechanics should be re-134 
defined.  Thus, we propose a new definition for our research domain: “Biomechanics is the 135 
study of living organisms as mechanistic systems”.  Wherever there is space for a 136 
mechanistic investigation, biomechanics steps in, with its quantitative observations made over 137 
space and time and across space-time scales, with its mechanistic theories, and with its 138 
progression of experimental falsifications from the most controllable experiments to the 139 
clinical experimentation. 140 
In conclusion, biomechanics-based in silico medicine is a new science of life, based on the 141 
conviction that the book of nature, including living organisms, is written in the language of 142 
mathematics, and on the arrogance that we can eventually, one day, understand that book.  143 
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